FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a monospecific antibody or its antigen-binding fragment that binds to CXCR4 as well as a pharmaceutical composition containing it and a diagnostic kit. Also disclosed is a polynucleotide encoding the above antibody or a fragment thereof. The invention also relates to a method for detecting CXCR4-expressing malignant cells in a mammalian individual using the above antibody or a fragment thereof.
EFFECT: invention may also be effective in treatment of a malignant neoplasm expressing CXCR4.
9 cl, 2 dwg, 9 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| DIVALENT BISPECIFIC CHIMERIC ANTIBODY COMPRISING HETERODIMER BASED ON MHC OR MHC-LIKE PROTEINS | 2021 |
|
RU2820683C2 |
| ANTIBODIES AGAINST A5 REPRESENTATIVE OF 19 FAMILY WITH SIMILARITY OF SEQUENCES AND THEIR APPLICATION METHOD | 2019 |
|
RU2785436C2 |
| ANTIBODY SPECIFICALLY BINDING TO N-TERMINAL REGION OF LYSYL-TRNA-SYNTHETASE EXPOSED ON CELL MEMBRANE | 2018 |
|
RU2739393C1 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| ANTIBODY FOR SPECIFIC BINDING TO N-TERMINAL DOMAIN OF LYSYL-TRNA SYNTHETASE EXPOSED ON EXTRACELLULAR MEMBRANE | 2019 |
|
RU2781304C1 |
| ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND ITS USE | 2019 |
|
RU2789757C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
